comparemela.com

Collaboration Fee News Today : Breaking News, Live Updates & Top Stories | Vimarsana

QSAM Biosciences Signs Term Sheet to be Acquired by Telix Pharmaceuticals; Receives $2 Million Pre-Closing Collaboration and Option Fee

Austin, TX, Nov. 14, 2023 (GLOBE NEWSWIRE) QSAM Biosciences Inc. (OTCQB: QSAM), a company developing therapeutic radiopharmaceuticals for the treatment of primary and secondary bone cancer and related conditions, has signed a non-binding term sheet (the “Term Sheet”) with Telix Pharmaceuticals (US) Inc., a subsidiary of Telix Pharmaceuticals Limited (ASX: TLX) (collectively, “Telix”) providing material terms for the acquisition of the Company by Telix by means of a merger (the “Acquisition”).

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.